Home Alzheimer’s Disease FDA Accepts BLA for Proposed Biosimilar to Bevacizumab, MYL-1402O

FDA Accepts BLA for Proposed Biosimilar to Bevacizumab, MYL-1402O

The FDA accepted a biologics license application (BLA) for MYL-1402O, a proposed biosimilar to bevacizumab (Avastin), for review under the 351(k) pathway, according to Biocon Biologics and Mylan, the agent’s developer.

The BLA is seeking approval of MYL-1402O for first-line and second-line treatment of patients with metastatic colorectal cancer in combination with fluorouracil-based chemotherapy, as well as first-line use for patients with non-squamous non-small cell lung cancer (NSCLC), recurrent glioblastoma, metastatic renal cell carcinoma in combination with interferon alfa, and persistent, recurrent, or metastatic cervical cancer. 

A goal date under the Biosimilar User Fee Act (BsUFA) was set for December 27, 2020. The proposed biosimilar is currently available in India and other developing markets. 

“As we continue toward our goal of expanding access to cancer treatments…

Continue Reading to the Source


Please enter your comment!
Please enter your name here

Most Popular

please help us fundraise (501c3 non-profit) : braincancer

I work with OurBrainBank, a start-up non-profit dedicated to moving glioblastoma from terminal to treatable, powered by patients.We're a registered 501c3 non-profit in the...

Cancer and Mental Health Re-post : braincancer

Hello!I would like to thank everyone who participated in my survey these past few months! I received a tremendous response and I truly, truly...

I put my feelings in music. : braincancer

Song LinkHi amigos. My 2year old son has been battling cancer for nearly 6 months and this song is just a expression of my...

Recent Comments